Figure 2 from Passenger Gene Coamplifications Create Collateral Therapeutic Vulnerabilities in Cancer

Passenger genes are frequently coamplified with oncogenes in cancers and can be associated with distinct dependencies. A, The mean number of passenger genes coamplified with oncogenes compared with the frequency of oncogene amplifications in cancers (dot size presents incidence passenger gene coamplification). B, Number of cancer cell lines in CCLE with an oncogene amplification compared with the number of cell lines with passenger coamplification (oncogenes for which sufficient dependency information is available in the DepMap are marked in red). C, Chromosome 2 schematic highlighting the area of MYCN amplification and passenger genes recurrently included on the amplicon (top). Upset plot (bottom) for the coamplification frequency of three passenger genes, NBAS, DDX1, and FAM49A, identified on the MYCN amplicon in a cohort of 556 neuroblastomas. D, Top 10 GO ontology terms enriched for collateral lethal targets associated with DDX1-MYCN coamplifications (TOR complex labeled in red). E, Difference in gene dependency scores between cancer cell lines with DDX1-MYCN coamplification vs. cell lines with MYCN amplifications compared with the log-transformed P values (Wilcoxon; candidate collateral lethal dependencies in DDX1-MYCN coamplified cancer cells, blue; mTORC1 complex, red).